Diseases of Bearded Dragons Thomas H
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Intelligence of Bearded Dragons Sydney Herndon
Murray State's Digital Commons Honors College Theses Honors College Spring 4-26-2021 Intelligence of Bearded Dragons sydney herndon Follow this and additional works at: https://digitalcommons.murraystate.edu/honorstheses Part of the Behavior and Behavior Mechanisms Commons Recommended Citation herndon, sydney, "Intelligence of Bearded Dragons" (2021). Honors College Theses. 67. https://digitalcommons.murraystate.edu/honorstheses/67 This Thesis is brought to you for free and open access by the Honors College at Murray State's Digital Commons. It has been accepted for inclusion in Honors College Theses by an authorized administrator of Murray State's Digital Commons. For more information, please contact [email protected]. Intelligence of Bearded Dragons Submitted in partial fulfillment of the requirements for the Murray State University Honors Diploma Sydney Herndon 04/2021 i Abstract The purpose of this thesis is to study and explain the intelligence of bearded dragons. Bearded dragons (Pogona spp.) are a species of reptile that have been popular in recent years as pets. Until recently, not much was known about their intelligence levels due to lack of appropriate research and studies on the species. Scientists have been studying the physical and social characteristics of bearded dragons to determine if they possess a higher intelligence than previously thought. One adaptation that makes bearded dragons unique is how they respond to heat. Bearded dragons optimize their metabolic functions through a narrow range of body temperatures that are maintained through thermoregulation. Many of their behaviors are temperature dependent, such as their speed when moving and their food response. When they are cold, these behaviors decrease due to their lower body temperature. -
Niche Modeling for the Genus Pogona (Squamata: Agamidae) in Australia: Predicting Past (Late Quaternary) and Future (2070) Areas of Suitable Habitat
Niche modeling for the genus Pogona (Squamata: Agamidae) in Australia: predicting past (late Quaternary) and future (2070) areas of suitable habitat Julie E. Rej1,2 and T. Andrew Joyner2 1 Department of Wildlife Ecology, The Wilds, Cumberland, OH, USA 2 Department of Geosciences, East Tennessee State University, Johnson City, TN, USA ABSTRACT Background: As the climate warms, many species of reptiles are at risk of habitat loss and ultimately extinction. Locations of suitable habitat in the past, present, and future were modeled for several lizard species using MaxEnt, incorporating climatic variables related to temperature and precipitation. In this study, we predict where there is currently suitable habitat for the genus Pogona and potential shifts in habitat suitability in the past and future. Methods: Georeferenced occurrence records were obtained from the Global Biodiversity Information Facility, climate variables (describing temperature and precipitation) were obtained from WorldClim, and a vegetation index was obtained from AVHRR satellite data. Matching climate variables were downloaded for three different past time periods (mid-Holocene, Last Glacial Maximum, and Last Interglacial) and two different future projections representative concentration pathways (RCPs 2.6 and 8.5). MaxEnt produced accuracy metrics, response curves, and probability surfaces. For each species, parameters were adjusted for the best possible output that was biologically informative. Results: Model results predicted that in the past, there was little suitable habitat for P. henrylawsoni and P. microlepidota within the areas of their current range. Past areas of suitable habitat for P. barbata were predicted to be similar to the current 16 March 2018 Submitted prediction. Pogona minor and P. -
Drug Consumption in 2017 - 2020
Page 1 Drug consumption in 2017 - 2020 2020 2019 2018 2017 DDD/ DDD/ DDD/ DDD/ 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital 1000 inhab./ Hospital ATC code Subgroup or chemical substance day % day % day % day % A ALIMENTARY TRACT AND METABOLISM 322,79 3 312,53 4 303,08 4 298,95 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12,82 4 10,77 6 10,46 7 A01AA Caries prophylactic agents 11,90 3 10,48 4 8,42 5 8,45 7 A01AA01 sodium fluoride 11,90 3 10,48 4 8,42 5 8,45 7 A01AA03 olaflur 0,00 - 0,00 - 0,00 - 0,00 - A01AB Antiinfectives for local oral treatment 2,36 8 2,31 7 2,31 7 2,02 7 A01AB03 chlorhexidine 2,02 6 2,10 7 2,09 7 1,78 7 A01AB11 various 0,33 21 0,21 0 0,22 0 0,24 0 A01AD Other agents for local oral treatment 0,02 0 0,03 0 0,04 0 - - A01AD02 benzydamine 0,02 0 0,03 0 0,04 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 71,13 3 69,32 3 68,35 3 A02A ANTACIDS 2,23 1 2,22 1 2,20 1 2,30 1 A02AA Magnesium compounds 0,07 22 0,07 22 0,08 22 0,10 19 A02AA04 magnesium hydroxide 0,07 22 0,07 22 0,08 22 0,10 19 A02AD Combinations and complexes of aluminium, 2,17 0 2,15 0 2,12 0 2,20 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 2,15 0 2,12 0 2,20 0 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 68,91 3 67,12 3 66,05 4 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 0,74 4 1,10 4 1,11 5 A02BA02 ranitidine 0,00 1 0,63 3 0,99 3 0,99 4 A02BA03 famotidine 0,16 7 0,11 8 0,11 10 0,12 9 A02BB Prostaglandins 0,04 62 -
Bearded Dragon (Pogona Vitticeps) Care Compiled by Dr
Bearded Dragon (Pogona vitticeps) Care Compiled by Dr. Dayna Willems Brief Description Native to the arid regions of Australia, bearded dragons are popular pets in captivity due to their docile nature and fairly basic care requirements compared to other reptiles. Adults can get up to two feet in length. There are several color morphs available like citrus, tangerine, and reds, and then several based on their scale texture as well. Lifespan With good care the average lifespan is about 8-10 years. Sexing Determining the gender of your bearded dragon can be difficult, especially as juveniles. Beard color is not a reliable indicator. Males will head bob to attract a female but some females will also head bob as a show of dominance. If you look at the underside of the tail just past the vent males should have two bulges side by side where the hemipenes (reproductive organs) sit in the base of the tail. Females will not have this. If your beardie's hemipenes briefly come out of the body while defecating then it is definitely male. Males also tend to have larger femoral pores as adults that can fill with waxy substance (normal). Caging • Juveniles: At least 20 gallon tank. • Adults: At least 40 gallon tank. • One bearded dragon per cage. Substrate • Newspaper, artificial turf like reptile carpet, flat stones or no floor covering are best. • AVOID sand (especially calcium sand) and bark/mulch should - your dragon might consume sand or fine- particle products on the cage floor, and this could lead to intestinal impaction. • A flat rock under the basking light will warm evenly and provide a good basking spot. -
Dietary Supplements Compendium Volume 1
2015 Dietary Supplements Compendium DSC Volume 1 General Notices and Requirements USP–NF General Chapters USP–NF Dietary Supplement Monographs USP–NF Excipient Monographs FCC General Provisions FCC Monographs FCC Identity Standards FCC Appendices Reagents, Indicators, and Solutions Reference Tables DSC217M_DSCVol1_Title_2015-01_V3.indd 1 2/2/15 12:18 PM 2 Notice and Warning Concerning U.S. Patent or Trademark Rights The inclusion in the USP Dietary Supplements Compendium of a monograph on any dietary supplement in respect to which patent or trademark rights may exist shall not be deemed, and is not intended as, a grant of, or authority to exercise, any right or privilege protected by such patent or trademark. All such rights and privileges are vested in the patent or trademark owner, and no other person may exercise the same without express permission, authority, or license secured from such patent or trademark owner. Concerning Use of the USP Dietary Supplements Compendium Attention is called to the fact that USP Dietary Supplements Compendium text is fully copyrighted. Authors and others wishing to use portions of the text should request permission to do so from the Legal Department of the United States Pharmacopeial Convention. Copyright © 2015 The United States Pharmacopeial Convention ISBN: 978-1-936424-41-2 12601 Twinbrook Parkway, Rockville, MD 20852 All rights reserved. DSC Contents iii Contents USP Dietary Supplements Compendium Volume 1 Volume 2 Members . v. Preface . v Mission and Preface . 1 Dietary Supplements Admission Evaluations . 1. General Notices and Requirements . 9 USP Dietary Supplement Verification Program . .205 USP–NF General Chapters . 25 Dietary Supplements Regulatory USP–NF Dietary Supplement Monographs . -
Adenoviruses in Free-Ranging Australian Bearded Dragons
Veterinary Microbiology 234 (2019) 72–76 Contents lists available at ScienceDirect Veterinary Microbiology journal homepage: www.elsevier.com/locate/vetmic Adenoviruses in free-ranging Australian bearded dragons (Pogona spp.) T ⁎ Timothy H Hyndmana, Jonathon G Howardb, Robert JT Doneleyc, a Murdoch University, School of Veterinary Medicine, Murdoch, Western Australia, 6150, Australia b Exovet Pty Ltd., East Maitland, New South Wales, 2323, Australia c UQ Veterinary Medical Centre, University of Queensland, School of Veterinary Science, Gatton, Queensland 4343, Australia ARTICLE INFO ABSTRACT Keywords: Adenoviruses are a relatively common infection of reptiles globally and are most often reported in captive Helodermatid adenovirus 2 central bearded dragons (Pogona vitticeps). We report the first evidence of adenoviruses in bearded dragons in Atadenovirus their native habitat in Australia. Oral-cloacal swabs and blood samples were collected from 48 free-ranging Diagnostics bearded dragons from four study populations: western bearded dragons (P. minor minor) from Western Australia Diagnosis (n = 4), central bearded dragons (P. vitticeps) from central Australia (n = 2) and western New South Wales (NSW) (n = 29), and coastal bearded dragons (P. barbata) from south-east Queensland (n = 13). Samples were tested for the presence of adenoviruses using a broadly reactive (pan-adenovirus) PCR and a PCR specific for agamid adenovirus-1. Agamid adenovirus-1 was detected in swabs from eight of the dragons from western NSW and one of the coastal bearded dragons. Lizard atadenovirus A was detected in one of the dragons from western NSW. Adenoviruses were not detected in any blood sample. All bearded dragons, except one, were apparently healthy and so finding these adenoviruses in these animals is consistent with bearded dragons being natural hosts for these viruses. -
Pharmaceutical Appendix to the Tariff Schedule 2
Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9 -
Calcium – ORAL 2019 Newborn Use Only
Calcium – ORAL 2019 Newborn Use Only Alert Multiple forms of calcium exist with varying amounts of elemental calcium expressed in varying units. Therefore careful attention is required in prescription and administration of calcium to avoid over- or under-dosing. Conversion factor for elemental Ca: 1 mg = 0.025 mmol = 0.05 mEq. Do not give calcium solutions and sodium bicarbonate simultaneously by the same route to avoid precipitation. Do not mix with any medication that contains phosphates, carbonates, sulfates or tartrates. Separate doses of the following by at least 2 hours: phosphate, iron, thyroxine and phenytoin. Indication Oral calcium supplement to prevent / treat calcium deficiency. Asymptomatic hypocalcaemia. Action Calcium is essential for the functional integrity of the nervous, muscular, skeletal and cardiac systems and for clotting function. Drug Type Mineral. Trade Name CalSource Ca1000 effervescent tablets (Novartis). If required: Calcium Gluconate Injection (Phebra) (calcium 0.22 mmol/mL). Calcium Chloride Injection (Phebra) 10% (calcium 0.68 mmol/mL). Maximum Dose Oral – 5.5 mmol/kg Presentation Calcium carbonate, calcium lactate gluconate (CalSource Ca1000) effervescent tablets contain calcium carbonate 1.8 g, calcium lactate gluconate 2.3 g (equivalent to 1 g or 25 mmol of elemental calcium) and sodium 136.9 mg (5.95 mmol). If required: Calcium gluconate 10% 10 mL vial contains 0.22 mmol/mL of elemental calcium. Calcium chloride 10% 10 mL vial contains 0.68 mmol/mL of elemental calcium. Dosage/Interval Dose can vary. Estimate the calcium intake from all sources before prescribing oral calcium. Recommended total daily intake of elemental calcium from all sources: 120–200 mg/kg/day (3–5 mmol/kg/day). -
Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services
Australian Statistics on Medicines 1997 Commonwealth Department of Health and Family Services Australian Statistics on Medicines 1997 i © Commonwealth of Australia 1998 ISBN 0 642 36772 8 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be repoduced by any process without written permission from AusInfo. Requests and enquiries concerning reproduction and rights should be directed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra, ACT 2601. Publication approval number 2446 ii FOREWORD The Australian Statistics on Medicines (ASM) is an annual publication produced by the Drug Utilisation Sub-Committee (DUSC) of the Pharmaceutical Benefits Advisory Committee. Comprehensive drug utilisation data are required for a number of purposes including pharmacosurveillance and the targeting and evaluation of quality use of medicines initiatives. It is also needed by regulatory and financing authorities and by the Pharmaceutical Industry. A major aim of the ASM has been to put comprehensive and valid statistics on the Australian use of medicines in the public domain to allow access by all interested parties. Publication of the Australian data facilitates international comparisons of drug utilisation profiles, and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. The data available in the ASM represent estimates of the aggregate community use (non public hospital) of prescription medicines in Australia. In 1997 the estimated number of prescriptions dispensed through community pharmacies was 179 million prescriptions, a level of increase over 1996 of only 0.4% which was less than the increase in population (1.2%). -
Code of Practice Captive Reptile and Amphibian Husbandry Nature Conservation Act 1992
Code of Practice Captive Reptile and Amphibian Husbandry Nature Conservation Act 1992 ♥ The State of Queensland, Department of Environment and Science, 2020 Copyright protects this publication. Except for purposes permitted by the Copyright Act, reproduction by whatever means is prohibited without prior written permission of the Department of Environment and Science. Requests for permission should be addressed to Department of Environment and Science, GPO Box 2454 Brisbane QLD 4001. Author: Department of Environment and Science Email: [email protected] Approved in accordance with section 174A of the Nature Conservation Act 1992. Acknowledgments: The Department of Environment and Science (DES) has prepared this code in consultation with the Department of Agriculture, Fisheries and Forestry and recreational reptile and amphibian user groups in Queensland. Human Rights compatibility The Department of Environment and Science is committed to respecting, protecting and promoting human rights. Under the Human Rights Act 2019, the department has an obligation to act and make decisions in a way that is compatible with human rights and, when making a decision, to give proper consideration to human rights. When acting or making a decision under this code of practice, officers must comply with that obligation (refer to Comply with Human Rights Act). References referred to in this code- Bustard, H.R. (1970) Australian lizards. Collins, Sydney. Cann, J. (1978) Turtles of Australia. Angus and Robertson, Australia. Cogger, H.G. (2018) Reptiles and amphibians of Australia. Revised 7th Edition, CSIRO Publishing. Plough, F. (1991) Recommendations for the care of amphibians and reptiles in academic institutions. National Academy Press: Vol.33, No.4. -
Australian Statistics on Medicines 1999–2000
Commonwealth Department of Health and Ageing Australian Statistics on Medicines 1999–2000 © Commonwealth of Australia 2003 ISBN 0 642 82184 4 This work is copyright. Apart from any use as permitted under the Copyright Act 1968, no part may be reproduced by any process without prior written permission from the Commonwealth available from AusInfo. Requests and inquiries concerning reproduction and rights should be addressed to the Manager, Legislative Services, AusInfo, GPO Box 1920, Canberra ACT 2601. Publications Approval Number: 3183 (PA7270) FOREWORD Comprehensive and valid statistics on use of medicines by Australians in the public domain should be accessible to all interested parties. From the first edition in 1992 until 1999 the Drug Utilisation SubCommittee (DUSC) produced the Australian Statistics on Medicines (ASM) for each calendar year to 1998. It is pleasing indeed to be able to present these again this year, with the inclusion of estimates for the years since the last edition. A continuous data set representing estimates of the aggregate community use (non public hospital) of prescription medicines in Australia is a key tool for the Australian Medicines Policy. The ASM presents dispensing data on most drugs marketed in Australia and is the only current source of data in Australia to cover all prescription medicines dispensed in the community. Drug utilisation data can assist the targeting and evaluation of quality use of medicines initiatives, and the evaluation of changes to the availability of medicines. It is also needed for pharmacosurveillance by regulatory and financing authorities and by the Pharmaceutical Industry. Publication of the Australian data also facilitates international comparisons of drug utilisation profiles and encourages international collaboration on drug utilisation research particularly in relation to enhancing the quality use of medicines and health outcomes. -
List of Annexures Annexure – I Plant Layout Annexure – II Manufacturing Process Annexure – III Details of Storage of So
List of Annexures Annexure – I Plant Layout Annexure – II Manufacturing Process Annexure – III Details of Storage of Solvents Annexure – IV Water Balance & Details of Treatment and disposal of Effluent Annexure – V Details of Treatment and Disposal of Solid Waste Annexure – VI List of Raw materials & Quantity of Consumption Annexure – VII Point Source Emissions – Stack Emission Characteristics Annexure – VIII Details of Fugitive Emissions Annexure – IX Risk Identification Annexure – X Topo Map & Administrative Set-up Map Annexures 1 GCPL ANNEXURE – I PLANT LAYOUT Annexures 2 GCPL Annexures 3 GCPL Annexures 4 GCPL ANNEXURE – II MANUFACTURING PROCESS Annexures 5 GCPL Manufacturing Process Existin g Calcium Gluconate Gluconic Acid procured from market is neutralized with Calcium carbonate, filtered, crystallised, centrifuged, dried, milled and packed. NEUTRALISATION FILTERATION CRYSTALLISATION PACKING MILLING DRYING CENTRIFUGING Alternate process for the manufacture of Calcium Gluconate Gluconic acid is neutralised with Calcium carbonate, filtered, crystallised, centrifuged, dried, milled and packed. NEUTRALISATION FILTRATION CRYSTALLISATION PACKING MILLING DRYING CENTRIFUGING Alternate process GLUCONO DELTA LACTONE + CaCO + WATER 3 FILTRATION CRYSTALLISATION (NEUTRALISATION) PACKING MILLING DRYING CENTRIFUGING Annexures 6 GCPL Sodium Gluconate Gluconic acid brought from the market is neutralised with Sodium bi-carbonate, filtered, concentrated, crystallised, centrifuged, dried, milled and packed. CONCENTRATION NEUTRALISATION FILTRATION CRYSTALLISATION